TABLE 1.
Biomarkers of platelets in cancer diagnosis and monitoring.
| Biomarkers | Correlation with platelets | Application | Reference |
|---|---|---|---|
| Platelet counts | Intrinsic characteristics | Nonmetastatic breast carcinoma/drug response | 123 , 163 , 170 , 171 |
| NRIP1 RNA, circRNA | The differential expression of RNA in platelets between healthy people and cancer patients | Pan‐cancer/NSCLC | 168 , 169 |
| PD‐L1 | PD‐L1 can be transferred from tumor cells to platelets; PD‐L1 levels of platelets can reveal the therapeutic effects | NSCLCs/immune‐checkpoint inhibitor therapies | 173 |
| PDGFR | Platelet‐derived growth factor is a proangiogenic factor isolated from human platelets, platelet‐derived growth factor receptor is a member of the caseomic acid protein kinase family, which can promote the chemotaxis, division and proliferation of cells in the body, growth and development, wound repair | Monitoring | 174 |
| VEGFRs | Platelets express or produce various proangiogenic factors like VEGFRs | GMB | 175 |
| Microparticles | Produced by platelets to detect the progression of cancer | NSCLC development | 176 |
| mRNA profiles | The expression mRNA of platelets between healthy people and cancer patients | Diagnosis/identification, location, malignancy, stage, and mutation of tumors | 177 , 178 , 179 , 180 , 181 |
Abbreviations: circRNA, circular RNA; NRIP1, nuclear receptor‐interacting protein 1; PDGFR, platelet‐derived growth factor receptor; PD‐L1, programmed death ligand 1; VEGFR, vascular endothelial growth factor receptor.